China SXT Pharmaceuticals, Inc.
SXTC · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.7% | -2.2% | -24.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 21.1% | 28.7% | 21.6% | 48.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -147.8% | -121.9% | -264.1% | -194.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -189.8% | -160.7% | -301% | -220.4% |
| EPS Diluted | -8.18 | -3.57 | -22.23 | -137.92 |
| % Growth | -129.1% | 83.9% | 83.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |